Skip to main content

Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Actuate Therapeutics

Start Date

May 14, 2020

End Date

February 13, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Actuate Therapeutics

Start Date

May 14, 2020

End Date

February 13, 2024